How to Engage T Cell in Myeloma

Description

The project aims to analyze tumor-infiltrating lymphocytes (TILs) in multiple myeloma patients treated with bispecific T-cell engager (bsAb) therapy, utilizing single-cell analyses to understand T-cell diversity, phenotype dynamics, and specificity. By correlating sequencing data with functional validation of anti-tumor reactivity, the study seeks to predict response to bsAb therapy. This integrated approach, combining clinical expertise from a leading myeloma center with bioinformatics infrastructure, aims to elucidate the immunological mechanisms of bsAb therapy and contribute to overcoming challenges in identifying and monitoring T-cell responses against various tumors. Ultimately, the project aims to develop a workflow for predicting bsAb therapy response, potentially advancing immunotherapy strategies for myeloma and other cancers.